微信公众号

官网二维码
中国癌症防治杂志

中国癌症防治杂志 ›› 2020, Vol. 12 ›› Issue (2): 227-231.doi: 10.3969/j.issn.1674-5671.2020.02.22

• 临床研究 • 上一篇    下一篇

18F-FDG PET/CT显像SUVmax预测非霍奇金淋巴瘤化疗疗效的价值

  

  1. 新疆医科大学第一附属医院核医学科, 肿瘤一科
  • 出版日期:2020-04-25 发布日期:2020-05-06
  • 通讯作者: 秦永德 E-mail：qdy0550@163.com

Implication of the SUVmax of 18F-FDG PET/CT images in predicting the therapeutic effects of non-Hodgkin's lymphoma

  1. Department of Nuclear Medicine, Department of Oncology，the First Affiliated Hospital of Xinjiang Medical University  
  • Online:2020-04-25 Published:2020-05-06

PDF (PC)

370

赞

摘要： 目的 探讨非霍奇金淋巴瘤（non-Hodgkin's lymphoma，NHL）患者治疗前18F-FDG PET/CT显像中最大标准化摄取值（SUVmax）与疗效的关系。方法 回顾性分析2017年7月—2019年3月在我科行18F-FDG PET/CT显像并经淋巴结活检确诊为NHL的146例患者的资料。根据国际工作组织淋巴瘤疗效评估标准（IWC）将化疗6个疗程的NHL患者分为有效组和无效组。分析SUVmax与临床病理特征及疗效的关系。结果 在NHL患者中，临床分期、恶性程度、病灶大小、坏死情况、骨髓浸润、治疗前血清乳酸脱氢酶、Ki-67阳性率与SUVmax有关（P＜0.05）；无效组治疗前SUVmax高于有效组（16.68±6.16 vs 12.16±5.27，t=4.654，P=0.001）；治疗前SUVmax评估NHL患者疗效的最佳截断值为14.836，对应的 AUC为0.835（95%CI：0.751~0.920），特异度为80.0%，敏感度为77.4%；治疗前SUVmax>14.836是影响NHL患者疗效的独立危险因素（OR=1.688，95%CI：1.179~2.418，P=0.007）。 结论 18F-FDG PET/CT显像中的SUVmax可评估NHL患者的化疗疗效。

关键词: 非霍奇金淋巴瘤, 18F-脱氧葡萄糖PET-CT显像, 最大标准化摄取值, 疗效

Abstract: Objective To explore the relationship between the maximum standard uptake value（SUVmax） of 18F-FDG PET/CT images and the therapeutic effects in patients with non-Hodgkin's lymphoma（NHL） before treatment. Methods The clinical data of 146 patients diagnosed with NHL by lymph node biopsy on 18F-FDG PET/CT images in our department from July 2017 to March 2019 were analyzed retrospectively. According to the International Working Organization Evaluation Standard for Lymphoma Efficacy（IWC），NHL patients with 6 courses of chemotherapy were divided into effective and ineffective groups to analyze the relationship between SUVmax and clini-copathological characteristics and curative effect. Results The clinical stage，malignancy，lesion size，necrosis，bone marrow infiltration，serum lactae dehydrogenase before treatment，Ki-67 positive rate in NHL patients were related to the SUVmax（P<0.05）. The SUVmax before treatment of the ineffective group was higher than that of the effective group（16.68±6.16 vs 12.16±5.27，t=4.654，P=0.001）. The optimal cut-off value of SUVmax to evaluate the efficacy of NHL patients before treatment was 14.836，the corresponding AUC was 0.835（95%CI：0.751-0.920），and the specificity was 80.0%，sensitivity was 77.4%. SUVmax>14.836 before treatment was an independent risk factor affecting the efficacy of NHL patients（OR=1.688， 95%CI：1.179-2.418，P=0.007）. Conclusion The SUVmax in 18F-FDG PET/CT images can be used to evaluate the efficacy of NHL patients.

Key words: Non-Hodgkin's lymphoma, 18F-fluorodeoxyglucose PET/CT images, Maximum standard uptake value, Efficacy

中图分类号: 

  • R733.1